Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison

INTRODUCTION: Cabozantinib and ramucirumab are approved for the treatment of adults with hepatocellular carcinoma (HCC) following prior sorafenib treatment; ramucirumab is restricted to use in patients with serum alpha-fetoprotein (AFP) ≥ 400 ng/mL. This matching-adjusted indirect comparison evaluat...

Descripción completa

Detalles Bibliográficos
Autores principales: Trojan, Jörg, Mollon, Patrick, Daniele, Bruno, Marteau, Florence, Martín, Lidia, Li, Yuxin, Xu, Qing, Piscaglia, Fabio, Zaucha, Renata, Sarker, Debashis, Lim, Ho Yeong, Venerito, Marino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107171/
https://www.ncbi.nlm.nih.gov/pubmed/33822328
http://dx.doi.org/10.1007/s12325-021-01700-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107171/
https://www.ncbi.nlm.nih.gov/pubmed/33822328
http://dx.doi.org/10.1007/s12325-021-01700-2

Ejemplares similares